- Home
- TKLF vs CLRB Comparison
TKLF vs CLRB Comparison
Compare TKLF & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKLF | CLRB |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 12.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | TKLF | CLRB |
|---|---|---|
| Price | $2.94 | $3.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.8K | ★ 34.5K |
| Earning Date | 12-19-2025 | 03-12-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $302,537,158.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.88 | ★ N/A |
| Revenue Growth | ★ 37.82 | N/A |
| 52 Week Low | $2.10 | $2.45 |
| 52 Week High | $4.32 | $20.60 |
Technical Indicators
Market Signals| Indicator | TKLF | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 46.81 |
| Support Level | $2.28 | $3.14 |
| Resistance Level | $3.19 | $3.42 |
| Average True Range (ATR) | 0.28 | 0.20 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 54.39 | 40.34 |
Price Performance
Historical ComparisonAbout TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.